Breast Cancer
EU Focus Meeting 2026
📍 SANA Malhoa Hotel, Av. José Malhoa 8, 1099-089 Lisbon, Portugal
🗓️ September 25 - 26, 2026
Last Year's Highlights
CME Accreditation
MD Education will seek accreditation from the European Accreditation Council for Continuing Medical Education (EACCME). This will allow participants of the academy to earn CME credits, enhancing the educational value of their experience.
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the Breast Cancer Focus Meeting 2026, to be held on September 25 - 26, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Breast Cancer research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Chairs of Breast Cancer EU Focus Meeting 2026:
Javier Cortés
University Hospital Vall d’Hebron, Barcelona, Spain
Virginia Kaklamani
UT Health, San Antonio, TX
Agenda & Faculty
Friday, 25 September, 2026 | Day 1
Session I: Updates in HER2 Positive Breast Cancer
Moderated by:
Javier Cortes
International Breast Cancer Center (IBCC), Barcelona, and IOB Madrid, Spain
11:05
How to Optimize Regimens in the Adjuvant Setting
Luis Marques da Costa Hospital de Santa Maria, Lisbon, Portugal
11:25
Treatment Landscape in Metastatic HER2 Positive Breast Cancer
Javier Cortes International Breast Cancer Center (IBCC), Barcelona, and IOB Madrid, Spain
11:45
Novel Anti HER2 Agents
Giampaolo Bianchini
San Raffaele Scientific Institute, Milan, Italy
Session II: Risk Reduction, Early Detection and Local Therapy
Moderated by:
Virginia Kaklamani
UT Health, San Antonio, TX
13:40
Can we Omit SLN Altogether?
Isabel T. Rubio
Clínica Universidad de Navarra, Spain
14:00
What’s New on Chemoprevention?
Andrea De Censi
Champalimaud Foundation, Lisbon, Portugal
Session III: HR+ Early Stage Breast Cancer
Moderated by:
Virginia Kaklamani
UT Health, San Antonio, TX
15:40
Who Needs OFS?
Alessandra Gennari University of Eastern Piedmont, Italy
16:00
Use of Genomic Tools to Help with Chemotherapy Decisions
Antonio Llombart-Cussac University Hospital Arnau de Vilanova, Lleida, Spain
16:20
Optimizing Endocrine Therapy in Early Stage Breast Cancer
Francois-Clement
Bidard
Institut Curie, Paris, France
Saturday, 26 September, 2026 | Day 2
Session IV: Triple Negative Breast Cancer
Moderated by:
Virginia Kaklamani UT Health, San Antonio, TX
09:05
The Future of ADCs: New Payloads, New Targets
Hope Rugo
City of Hope, Duarte, CA
09:25
How to Address High Risk TNBC
Ana Garrido-Castro
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
09:45
MRD: Should We Use it in Clinic?
Emmanouil Saloustros.
University of Thessaly, Volos, Greece
10:05
How Can We Define Low Risk TNBC
Marleen Kok
Netherlands Cancer Institute, Amsterdam, Netherlands
Session V: Breast Cancer: Difficult to Treat Situations
Moderated by:
Javier Cortés International Breast Cancer Center (IBCC), Barcelona, and IOB Madrid, Spain
11:05
CNS Metastases
Rupert Bartsch
Medical University of Vienna, Austria
11:25
Oligometastatic Breast Cancer
Antonio Llombart-Cussac University Hospital Arnau de Vilanova, Llieda, Spain
11:45
Anthracyclines en eBC
Peter Fasching
University Hospital Erlangen, Germany
12:05
Postmastectomy Radiation
Philip Poortmans
University of Antwerp, Belgium
Session VI: HR+ Metastatic Breast Cancer
Moderated by:
Virginia Kaklamani
UT Health, San Antonio, TX
14:20
What is the Optimal First-line Strategy?
Diogo Martins-Branco
University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
14:40
How to Treat MBC Beyond CDK 4/6 Inhibitors
Virginia Kaklamani. UT Health, San Antonio, TX
15:00
The Future of ADCs in HR+ MBC
Nicla La Verde
ASST Fatebenefratelli Sacco – Luigi Sacco University Hospital, Milan, Italy
Session VII: ADCs in MBC & Risk-Reducing Strategies: Optimizing the Right Approach
Moderated by:
Javier Cortes
International Breast Cancer Center (IBCC), Barcelona, and IOB Madrid, Spain
16:00
Mechanisms of Resistance to ADCs
Barbara Pistilli
Gustave Roussy Institute, Villejuif, France
16:20
Sequencing ADCs in Clinical Practice
Carlos H. Barrios
Hospital São Lucas of PUCRS, Porto Alegre, Brazil
16:40
BRCA1/2 & Risk-Reducing Strategies in MBC
Matteo Lambertini
Ente Ospedaliero Ospedali Galliera, Genoa, Italy
Cristina Anton
Lead Project Manager
How long has Cristina Anton been in the business?
Cristina Anton has been with MD Education since 2022.
About Cristina Anton
As a Lead Project Manager at MD Education’s Wigan office since 2022, I organize international medical conferences with a focus on breast cancer and inflammatory bowel disease (IBD). Originally from Romania, I have been based in the UK since 2015. My diverse background across sectors helps me deliver high-quality, impactful educational programs. I’m committed to excellence and continuous growth.
